439097-58-2

Usage

Chemical structure

A piperidinone derivative with a fluorine atom and a nitro group attached to a phenyl ring

Field of application

Medicinal chemistry and pharmaceutical research

Usage

Building block for the synthesis of biologically active compounds, potential drugs, or drug candidates

Unique structure

Valuable intermediate for the development of new chemical entities with therapeutic potential

Additional use

Reagent in organic synthesis for the preparation of other fluorinated and nitro-aromatic compounds

Upstream product

• 41661-47-6 piperidin-4-one 
• 369-34-6 3,4-difluoronitrobenzene 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 41979-39-9 4-piperidone hydrochloride 

Downstream Products

• 590421-70-8 1-(2-fluoro-4-nitrophenyl)-4-[(trimethylsilyl)oxy]-1,2,3,6-tetrahydropyridine 
• 252336-82-6 4-(1,4-dioxa-8-azaspiro[4.5]decan-8-yl)-3-fluoronitrobenzene 
• 1000052-70-9 1-(2-fluoro-4-nitrophenyl)-N-methylpiperidin-4-amine 

Relevant academic research and scientific papers

Compound for inhibiting cancer showing EGFR mutation and medical uses thereof

The present disclosure provides a compound of a specific chemical structure or a pharmaceutically acceptable salt thereof, which has the activity of inhibiting and/or degrading mutant EGFR protein. The present disclosure also provides a composition comprising such a compound or a pharmaceutically acceptable salt thereof. The present disclosure provides a pharmaceutical use of a compound according to the present disclosure, a salt thereof, and a composition comprising same for the treatment or prevention of cancer with EGFR mutation, especially lung cancer. The present disclosure also provides a method for treatment or prevention of EGFR mutation cancer, especially lung cancer, the method comprising administering an effective amount of the compound according to the present invention, a salt thereof, or a composition containing same to a subject in need of treatment.

ISOINDOLINONE AND INDAZOLE COMPOUNDS FOR THE DEGRADATION OF EGFR

The invention provides compounds that degrade the epidermal growth factor receptor (EGFR) including mutant forms via the ubiquitination of the EGFR protein and subsequent proteasomal degradation. The compounds are useful for the treatment of various cancers.

COMPOUNDS FOR TARGETED DEGRADATION OF BRD9

BRD9 protein degradation compounds or pharmaceutically acceptable salts thereof are provided for the treatment of disorders mediated by BRD9, including but not limited to abnormal cellular proliferation.

BRAF DEGRADERS

Present invention provides compounds that cause specifically the degradation of BRAF. The present compounds are useful for the treatment of various cancers.

Synthesis and antibacterial evaluation of novel oxazolidinone derivatives containing a piperidinyl moiety

In this article, a series of novel oxazolidinone derivatives containing a piperidinyl moiety was designed and synthesized. Their antibacterial activities were measured against S. aureus, MRSA, MSSA, LREF and VRE by MIC assay. Most of them exhibited potent activity against Gram-positive pathogens comparable to linezolid. Among them, compound 9h exhibited comparable activity with linezolid against human MAO-A for safety evaluation and showed moderate metabolism in human liver microsome. The most promising compound 9h, which showed remarkable antibacterial activity against S. aureus, MRSA, MSSA, LREF and VRE pathogens with MIC value of 0.25–1 μg/mL, was an interesting candidate for further investigation.

BIARYL DERIVATIVE AS GPR120 AGONIST

The present invention relates to a biaryl derivative expressed by the chemical formula 1, a method for producing the biaryl derivative, a pharmaceutical composition comprising same, and use of same, the biaryl derivative expressed by the chemical formula 1, as a GPR120 agonist, promoting GLP-1 generation in the gastro-intestinal tract, reducing insulin resistance in the liver, muscles and the like from anti-inflammatory activity in the macrophage, pancreatic cells and the like, and allowing effective use in prevention or treatment of inflammation or metabolic diseases such as diabetes, complications from diabetes, obesity, non-alcoholic fatty liver disease, fatty liver disease, and osteoporosis.

N-(3,4-disubstituted phenyl) salicylamide derivatives

A compound represented by the following formula (I) or a salt thereof: wherein R1, R2, R3 and R4 represent hydrogen atom, a halogen atom, cyano group, nitro group, a C1-4 alkyl group, a halogenated C

NOVEL TRIAZOLE COMPOUNDS: PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

The present invention relates to novel triazole compounds of formula (I), their prodrugs, their pharmaceutically acceptable salts and their stereoisomers thereof. The present invention also relates to a process for the preparation of the novel compound of

ANTIMICROBIAL 1-ARYL DIHYDROPYRIDONE COMPOUNDS

The present invention provides antibacterial agents of formula (I), or a pharmaceutically acceptable salt thereof, wherein A is a structure (i), (ii), (iii) or (iv); X is (a) NHC(=O)R1, (b) NHC(=S)R1, (c) NH-het1/sup

N-aryl-2-oxazolidinone-5-carboxamides and their derivatives

The present invention provides antibacterial agents having the formulae I, II, and III described herein.